Ordering FluMist® Quadrivalent


FluMist Quadrivalent is now available for online in-season ordering. It’s the only nasally administered flu vaccine that helps prevent influenza at the typical site of viral entry and infection—the nose1‑3

When ordering FluMist Quadrivalent, you may be eligible for:

Returns:
Prebook orders placed between January 1, 2014, and April 18, 2014, may be eligible for 25% returns.
Replacement:
Unused product that expires on or before January 31, 2015, is eligible for replacement. Follow your distributor’s instructions.

FluMist Quadrivalent is sold through distributors, not directly through MedImmune. The product is supplied in a package of 10 pre-filled, single-dose (0.2 mL) intranasal sprayers (NDC 66019-300-10). The single-dose intranasal sprayer (NDC 66019-300-01) contains no natural rubber latex1

 
 
 

Billing, Coding, and Reimbursement

If you have specific questions regarding billing, coding, or reimbursement, call the MedImmune Access 360 hotline at 1-866-470-5856.

You can find additional information on billing, coding, reimbursement, and other practice management issues at the Practice Support section of the American Academy of Pediatrics website.


Important Safety Information

FluMist® Quadrivalent

FluMist Quadrivalent is a vaccine indicated for active immunization of persons 2‑49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction to any vaccine component including egg protein, gentamicin, gelatin and arginine or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal). Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.

If Guillain‑Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks. FluMist Quadrivalent has not been studied in immunocompromised persons. The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established. FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2‑49 years, fever >100°F in children 2‑6 years, and sore throat in adults 18‑49 years. Among children 2‑17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18‑49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

Please see complete Prescribing Information for FluMist Quadrivalent, including Patient Information.

open

Select safety information

The most common solicited adverse reactions were runny nose or nasal congestion in all persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years.

Click the OPEN tab for Important Safety and Eligibility Information

Important Safety and Eligibility Information

FluMist Quadrivalent is a vaccine indicated for active immunization of persons 2‑49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction to any vaccine component including egg protein, gentamicin, gelatin and arginine or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal). Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.

If Guillain‑Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks. FluMist Quadrivalent has not been studied in immunocompromised persons. The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established. FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2‑49 years, fever >100°F in children 2‑6 years, and sore throat in adults 18‑49 years. Among children 2‑17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18‑49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

Please see complete Prescribing Information for FluMist Quadrivalent, including Patient Information.